Viral resistance of MOGS-CDG patients implies a broad-spectrum strategy against acute virus infections

Antiviral Therapy

Volumn 20, Issue 3, 2015, Pages 257-259

  Chang, Jinhong ^a   Block, Timothy M ^a   Guo, Ju Tao ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSIDASE; GLYCOSIDASE INHIBITOR; MANNOSYL OLIGOSACCHARIDE GLUCOSIDASE; UNCLASSIFIED DRUG; ALPHA GLUCOSIDASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CONGENITAL DISORDER OF GLYCOSYLATION TYPE 2B; GENETIC DISORDER; HEPATITIS B; HEPATITIS C; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN DEFICIENCY; INFLUENZA VIRUS A; MORPHOGENESIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS HEMORRHAGIC FEVER; VIRUS INFECTION; VIRUS REPLICATION; VIRUS RESISTANCE; AGAMMAGLOBULINEMIA; CONGENITAL DISORDER OF GLYCOSYLATION; DISEASE RESISTANCE; FEMALE; GENETICS; IMMUNOLOGY; MALE;

AGAMMAGLOBULINEMIA; ALPHA-GLUCOSIDASES; CONGENITAL DISORDERS OF GLYCOSYLATION; DISEASE RESISTANCE; FEMALE; HUMANS; MALE; VIRUS DISEASES;

EID: 84937564714     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2907     Document Type: Article

References (20)

1. Sadat MA, Moir S, Chun TW, et al. Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N Engl J Med 2014; 370:1615-1625.
2. De Praeter CM, Gerwig GJ, Bause E, et al. A novel disorder caused by defective biosynthesis of N-linked oligosaccharides due to glucosidase I deficiency. Am J Hum Genet 2000; 66:1744-1756.
3. Chang J, Block TM, Guo JT. Antiviral therapies targeting host ER alpha-glucosidases: current status and future directions. Antiviral Res 2013; 99:251-260.
4. Küster B, Wheeler SF, Hunter AP, et al. Sequencing of N-linked oligosaccharides directly from protein gels: in-gel deglycosylation followed by matrix-assisted laser desorption/ionization mass spectrometry and normal-phase high-performance liquid chromatography. Anal Biochem 1997; 250:82-101.
5. Ritchie G, Harvey DJ, Feldmann F, et al. Identification of N-linked carbohydrates from severe acute respiratory syndrome (SARS) spike glycoprotein. Virology 2010; 399:257-269.
6. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009; 9:465-479.
7. Chen ST, Lin YL, Huang MT, et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature 2008; 453:672-676.
8. Wu MF, Chen ST, Yang AH, et al. CLEC5A is critical for dengue virus-induced inflammasome activation in human macrophages. Blood 2013; 121:95-106.
9. Chen ST, Liu RS, Wu MF, et al. CLEC5A regulates Japanese encephalitis virus-induced neuroinflammation and lethality. PLoS Pathog 2012; 8:e1002655.
10. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471-478.
11. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313:670-673.
12. Ferrara C, Grau S, Jager C, et al. Unique carbohydratecarbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A 2011; 108:12669-12674.
13. Anthony RM, Nimmerjahn F. The role of differential IgG glycosylation in the interaction of antibodies with FcgammaRs in vivo. Curr Opin Organ Transplant 2011; 16:7-14.
14. Forthal DN, Gach JS, Landucci G, et al. Fc-glycosylation influences Fcgamma receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol 2010; 185:6876-6882.
15. Durantel D. Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Curr Opin Investig Drugs 2009; 10:860-870.
16. 3. J Acquir Immune Defic Syndr 1994; 7:139-147.
17. Norton PA, Menne S, Sinnathamby G, et al. Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks. Hepatology 2010; 52:1242-1250.
18. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000; 181:2-9.
19. Noble CG, Chen YL, Dong H, et al. Strategies for development of dengue virus inhibitors. Antiviral Res 2010; 85:450-462.
20. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508:402-405.